M Nakagawa1, Y Maruyama, M Osame
1Third Department of Internal Medicine, Faculty of Medicine, Kagoshima University.
Several treatments show promise for Human T-lymphotropic virus type 1-associated myelopathy (HAM). Fosfomycin (92%) and high-dose vitamin C (82%) demonstrated high efficacy in improving motor disability for HAM patients.
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Area of Science: